| Literature DB >> 31549014 |
Yoshio Haga1, Hiroaki Miyata2, Akira Tsuburaya3, Mitsukazu Gotoh2, Kazuhiro Yoshida4, Hiroyuki Konno2,5, Yasuyuki Seto6, Yoshiyuki Fujiwara7, Hideo Baba8.
Abstract
AIM: Gastric cancer is the second leading cause of cancer death worldwide. Surgery is the mainstay treatment for gastric cancer. There are no prediction models that examine the severity of postoperative morbidity. Herein, we constructed prediction models that analyze the risk for postoperative morbidity based on severity.Entities:
Keywords: National Clinical Database; gastric cancer; morbidity; risk model; surgery
Year: 2019 PMID: 31549014 PMCID: PMC6749953 DOI: 10.1002/ags3.12269
Source DB: PubMed Journal: Ann Gastroenterol Surg ISSN: 2475-0328
Demographic data of patients who underwent elective gastric cancer resection between 2011 and 2012 in Japan
| Development set (n = 77 423) | Validation set (n = 76 855) | |
|---|---|---|
| Preoperative factors | ||
| Age, y, mean (SD) | 69.3 (11.3) | 69.2 (11.3) |
| Male | 53 529 (69.1%) | 53 056 (69.0%) |
| Diabetes mellitus | 12 659 (16.4%) | 12 366 (16.1%) |
| COPD | 3032 (3.9%) | 3067 (4.0%) |
| Cerebrovascular disease | 2958 (3.8%) | 2890 (3.8%) |
| Previous PCI | 2002 (2.6%) | 1959 (2.5%) |
| Previous cardiac surgery | 906 (1.2%) | 900 (1.2%) |
| Previous PVD surgery | 407 (0.5%) | 443 (0.6%) |
| Bleeding disorder | 2709 (3.5%) | 2676 (3.5%) |
| Weight loss ≥10% | 4445 (5.7%) | 4474 (5.8%) |
| Respiratory distress, any | 1598 (2.1%) | 1519 (2.0%) |
| ADL, any assistance | 3295 (4.3%) | 3303 (4.3%) |
| Ascites | 1065 (1.4%) | 1096 (1.4%) |
| BMI, median (IQR) | 22.0 (19.8‐24.2) | 22.0 (19.8‐24.2) |
| ASA‐PS ≥3 | 7577 (9.8%) | 7366 (9.6%) |
| Disseminated disease | 1348 (1.7%) | 1276 (1.7%) |
| Laboratory data | ||
| WBC >11 000/μL | 1493 (1.9%) | 1482 (1.9%) |
| Platelet <80 000/μL | 384 (0.5%) | 363 (0.5%) |
| Albumin <4.0 g/dL | 27 811 (35.9%) | 27 310 (35.5%) |
| Na <135 mmol/L | 2357 (3.0%) | 2236 (2.9%) |
| Creatinine >1.2 mg/dL | 5356 (6.9%) | 5135 (6.7%) |
| AST >35 IU/mL | 6009 (7.8%) | 5950 (7.7%) |
| ALP >600 IU/mL | 467 (0.6%) | 481 (0.6%) |
| CRP >1.0 mg/dL | 6573 (8.5%) | 6428 (8.4%) |
| Prothrombin time‐INR >1.25 | 1866 (2.4%) | 1928 (2.5%) |
| Intraoperative factors | ||
| Blood loss, g, median (IQR) | 190 (70‐400) | 194 (70‐405) |
| Operation time, min, median (IQR) | 250 (196‐315) | 251 (196‐315) |
| Type of gastrectomy | ||
| Partial gastrectomy without LN dissection | 4577 (5.9%) | 4643 (6.0%) |
| Partial gastrectomy | 46 411 (59.9%) | 45 913 (59.7%) |
| Total gastrectomy | 23 832 (30.8%) | 23 735 (30.9) |
| Proximal gastrectomy | 647 (0.8%) | 673 (0.9%) |
| Total gastrectomy with splenectomy | 2277 (2.9%) | 2207 (2.9%) |
| Total gastrectomy with PS | 327 (0.4%) | 358 (0.5%) |
| Postoperative morbidity | ||
| Grade 2 | 12 806 (16.5%) | 12 828 (16.7%) |
| Grade 3 | 6006 (7.8%) | 6046 (7.9%) |
| Grade 4 | 1604 (2.1%) | 1552 (2.1%) |
| Grade 5 | 1069 (1.4%) | 1031 (1.3%) |
ADL, activities of daily living; ALP, alkaline phosphatase; ASA‐PS, American Society of Anesthesiologists Physical Status; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; INR, international normalized ratio; IQR, interquartile range; LN, lymph node; PCI, percutaneous coronary intervention; PS, pancreatosplenectomy; PVD, peripheral vascular disease; WBC, white blood cell count.
Coefficients of logistic regression models for postoperative morbidity
| Variables | Grade ≥2 | Grade ≥3 | Grade ≥4 | Grade 5 |
|---|---|---|---|---|
| Age, y | — | — | 0.244 | 0.291 |
| Distal gastrectomy without LN dissection | — | — | — | 0.231 |
| With colectomy | 0.568 | 0.541 | — | — |
| Total or proximal gastrectomy | 0.413 | 0.463 | 0.580 | 0.566 |
| With splenectomy | 0.523 | 0.413 | — | — |
| Male | — | 0.460 | 0.330 | 0.199 |
| Respiratory distress, any | 0.420 | — | 0.474 | 0.670 |
| Weight loss ≥10% | 0.271 | 0.286 | 0.431 | 0.534 |
| Previous PCI | 0.314 | 0.256 | 0.377 | 0.305 |
| Previous cardiac surgery | 0.253 | — | — | — |
| Previous PVD surgery | 0.314 | — | — | — |
| ADL, any assistance | 0.515 | 0.612 | 0.715 | 0.821 |
| Cerebrovascular disease | 0.403 | 0.292 | 0.509 | 0.412 |
| Ascites, any | 0.491 | 0.454 | 0.830 | 1.040 |
| COPD | 0.294 | 0.365 | 0.214 | — |
| PVD | — | 0.541 | — | — |
| Disseminated disease | 0.266 | 0.515 | 0.922 | 1.092 |
| Bleeding disorder | 0.561 | — | 0.766 | 0.691 |
| ASA‐PS ≥4 | 0.819 | 0.535 | 0.723 | — |
| ASA‐PS ≥3 | 0.360 | 0.336 | 0.410 | 0.423 |
| BMI >25 | — | — | 0.203 | — |
| BMI >26 | 0.287 | — | — | — |
| WBC >11 000/μL | 0.261 | — | 0.670 | 0.691 |
| Platelets <80 000/μL | 0.596 | 0.782 | 0.803 | 0.879 |
| Albumin <4.0 g/dL | 0.294 | 0.276 | — | — |
| Albumin <3.8 g/dL | — | — | 0.446 | 0.624 |
| Na <138 mmol/L | — | — | 0.379 | 0.463 |
| Na <135 mmol/L | 0.298 | — | — | — |
| Creatinine >2.0 mg/dL | — | — | 0.500 | — |
| Creatinine >1.2 mg/dL | — | 0.282 | 0.518 | — |
| AST >35 IU/mL | — | — | 0.290 | 0.341 |
| ALP >600 IU/mL | — | — | 0.781 | 0.868 |
| CRP >1.0 mg/dL | — | — | 0.276 | 0.322 |
| Prothrombin time‐INR >1.25 | — | — | 0.245 | 0.364 |
| Constant | −2.441 | −3.337 | −6.094 | −6.880 |
ADL, activities of daily living; ALP, alkaline phosphatase; ASA‐PS, American Society of Anesthesiologists Physical Status classification; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; INR, international normalized ratio; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; WBC, white blood cell count.
(Predicted event rate (p) for each outcome was calculated as follows: ln [p/(1 − p)] = β0 + ∑β X , where β0 is a constant, β is a coefficient, and X i is a variable).
"–" means no coefficients.
Figure 1Discriminative power of prediction models for postoperative morbidity in gastric cancer resection. Receiver operating characteristic curve analysis for each prediction model was carried out in a validation set (n = 76 855)
Figure 2Calibration plot of prediction models for postoperative morbidity in gastric cancer resection. Observed event rates (95% CI) were plotted with predicted event rates in 10 risk bands for each prediction model in the validation set (n = 76 855)
Risk of postoperative morbidity of patients classified as grade ≥2
| Risk band | Predicted event rates | Observed event rates (95% CI) |
|---|---|---|
| 1 | <8.5% | 6.4% (5.8% to 7.0%) |
| 2 | 8.5% to <10.0% | 8.9% (8.3% to 9.5%) |
| 3 | 10.0% to <11.4% | 11.3% (10.6% to 12.0%) |
| 4 | 11.4% to <12.7% | 12.2% (11.5% to 13.0%) |
| 5 | 12.7% to <14.3% | 13.8% (13.0% to 14.6%) |
| 6 | 14.3% to <16.2% | 16.3% (15.5% to 17.1%) |
| 7 | 16.2% to <18.3% | 18.5% (17.6% to 19.4%) |
| 8 | 18.3% to <21.5% | 20.5% (19.6% to 21.4%) |
| 9 | 21.5% to <27.0% | 24.6% (23.6% to 25.5%) |
| 10 | ≥27.0% | 34.2% (33.2% to 35.3%) |
Risk of postoperative morbidity of patients classified as grade ≥3
| Risk band | Predicted event rates | Observed event rates (95% CI) |
|---|---|---|
| 1 | <3.5% | 2.6% (2.2% to 2.9%) |
| 2 | 3.5% to <4.3% | 3.8% (3.3% to 4.2%) |
| 3 | 4.3% to <4.8% | 4.8% (4.3% to 5.2%) |
| 4 | 4.8% to <6.2% | 5.3% (4.8% to 5.8%) |
| 5 | 6.2% to <7.1% | 6.4% (5.9% to 7.0%) |
| 6 | 7.1% to <8.2% | 7.3% (6.7% to 7.8%) |
| 7 | 8.2% to <9.8% | 8.0% (7.4% to 8.6%) |
| 8 | 9.8% to <12.8% | 9.6% (9.0% to 10.3%) |
| 9 | 12.8% to <25.2% | 12.2% (11.5% to 12.9%) |
| 10 | ≥25.2% | 18.9% (18.1% to 19.8%) |